1. Reduced bioavailability of atenolol in man: the role of bile acids
- Author
-
M.J. Story, T. Laudanski, S.G. Barnwell, M. Dwyer, David Attwood, S.K. Cole, and P. Guard
- Subjects
medicine.medical_specialty ,Bile acid ,medicine.drug_class ,Chemistry ,Cmax ,Pharmaceutical Science ,Pharmacology ,Atenolol ,Bioavailability ,Endocrinology ,Pharmacokinetics ,In vivo ,Oral administration ,Internal medicine ,Healthy volunteers ,medicine ,cardiovascular diseases ,circulatory and respiratory physiology ,medicine.drug - Abstract
The effect of bile acids on atenolol bioavailability was assessed using a randomised two-way cross-over study in eight healthy volunteers. Single dose kinetics were studied in fasted subjects using either Tenormin® or a preparation of atenolol containing bile acids. The co-administration of bile acids with atenolol resulted in a 30% reduction in AUC and a 28% reduction in Cmax compared to Tenormin®. No significant differences in tmax or t 1 2 were detected. The potential clinical implications of the interactions between atenolol and bile acids in vivo are discussed, together with a possible explanation for the observed effects of food on atenolol bioavailability.
- Published
- 1993
- Full Text
- View/download PDF